[This corrects the article DOI: 10.18632/oncotarget.1628.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544396 | PMC |
| http://dx.doi.org/10.18632/oncotarget.26997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic rewiring in skin epidermis drives tolerance to oncogenic mutations.
Nat Cell Biol
January 2025
Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
Skin epithelial stem cells correct aberrancies induced by oncogenic mutations. Oncogenes invoke different strategies of epithelial tolerance; while wild-type cells outcompete β-catenin-gain-of-function (βcatGOF) cells, Hras cells outcompete wild-type cells. Here we ask how metabolic states change as wild-type stem cells interface with mutant cells and drive different cell-competition outcomes.
View Article and Find Full Text PDFHydroxychloroquine enhances insulin sensitivity and ameliorates abnormal lipid metabolism in obese women with polycystic ovary syndrome.
BMC Endocr Disord
January 2025
Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250011, China.
Background: Hydroxychloroquine (HCQ) is frequently utilized in rheumatic immune disorders and has been discovered to exert hypoglycemic effects in some obese women with polycystic ovary syndrome(PCOS), however, the precise efficacy and mechanism of action remain ambiguous.
Objective: To examine the impact of HCQ on glucose and lipid metabolism as well as sex hormone levels in obese women with PCOS.
Method: Fifty obese women with PCOS were randomly allocated into two groups: HCQ group (n = 25) and metformin (MET) group (n = 25).
A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).
Clin Diabetes Endocrinol
December 2024
Glenmark Pharmaceuticals, Mumbai, India.
Aims: The ICMR INDIAB-17 study revealed a diabetes prevalence of 11.4% in India, emphasizing the need for effective treatment for glycemic control. A Phase IV study was conducted to evaluate the safety and efficacy of a Fixed Dose Combination (FDC) of Remogliflozin, Metformin and Vildagliptin (RMV) in Type 2 Diabetes Mellitus (T2DM) patients uncontrolled on Metformin plus SGLT2 inhibitor or Metformin plus DPP4 inhibitor dual therapy.
View Article and Find Full Text PDFSGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.
Diabetes Obes Metab
December 2024
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Background: Epicardial adipose tissue (EAT) plays a significant role in several cardiovascular diseases. As a correctable risk factor and potential therapeutic target, reducing EAT has multiple cardiovascular benefits, especially in those with abnormal glucolipid metabolism. The objective of this research was to compare the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and exercise on the thickness of EAT and indicators of glucolipid metabolism in people with type 2 diabetes mellitus (T2DM), obesity, and T2DM with obesity.
View Article and Find Full Text PDFInfluence of gut bile acid composition on the glucose-lowering effect and safety of metformin.
Br J Clin Pharmacol
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.
Article Synopsis
- The study investigates how cholestyramine, a bile acid sequestrant, influences the effectiveness of metformin in lowering blood glucose levels by altering intestinal bile acid composition.
- It involved healthy male adults in a two-period crossover design, where participants received metformin alone in the first period and with cholestyramine in the second, measuring various glucose response parameters.
- Results showed that cholestyramine further decreased the glucose-lowering effects of metformin and improved the associated side effect of diarrhea in some participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!